ReviewVeterinary pathology2022
Influence of SARS-CoV-2 on airway mucus production: A review and proposed model.
Review in Veterinary pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Human iPSC-derived airway models enable comparative analysis of SARS-CoV-2 infection in healthy and COPD bronchial epithelium.iScience · 2026Article
- AI-Based Quantitative HRCT for In-Hospital Adverse Outcomes and Exploratory Assessment of Reinfection in COVID-19.Diagnostics (Basel, Switzerland) · 2025Article
- Live imaging of airway epithelium reveals that mucociliary clearance modulates SARS-CoV-2 spread.Nature communications · 2024Article
- Anti-COVID-19 Potential of Withaferin-A and Caffeic Acid Phenethyl Ester.Current topics in medicinal chemistry · 2024Article
- An analysis of central venous catheter-related bloodstream infections in patients treated in a Swedish Covid-19 intensive care unit.SAGE open medicine · 2024Article
- Validation of airway porcine epithelial cells as an alternative to human in vitro preclinical studies.Scientific reports · 2023Article
- Immunohistochemical detection of MUC5AC and MUC5B mucins in ferrets.BMC research notes · 2023Article
- Mucociliary clearance augmenting drugs block SARS-CoV-2 replication in human airway epithelial cells.American journal of physiology. Lung cellular and molecular physiology · 2023Article
- Oxidative stress inducesFASEB bioAdvances · 2023Article
- Mucociliary Clearance Augmenting Drugs Block SARS-Cov-2 Replication in Human Airway Epithelial Cells.bioRxiv : the preprint server for biology · 2023Article
- Review
- Taming the SARS-CoV-2-mediated proinflammatory response with BromAcFrontiers in immunology · 2023Article
- Mathematical modeling of respiratory viral infection and applications to SARS-CoV-2 progression.Mathematical methods in the applied sciences · 2022Article
- Animal models for studying COVID-19, prevention, and therapy: Pathology and disease phenotypes.Veterinary pathology · 2022Review
- The ratio of serum LL-37 levels to blood leucocyte count correlates with COVID-19 severity.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Coronavirus disease 2019 (COVID-19) is a worldwide pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has affected millions of lives. Individuals who survive severe COVID-19 can experience sustained respiratory symptoms that persist for months after initial infection. In other airway diseases, abnormal airway mucus contributes to sustained airway symptoms. However, the impact of SARS-CoV-2 on airway mucus has received limited attention. In the current review, we assess literature describing the impact of SARS-CoV-2 on airway pathophysiology with specific emphasis on mucus production. Accumulating evidence suggests that the 2 major secreted airway mucin glycoproteins, MUC5AC and MUC5B, are abnormal in some patients with COVID-19. Aberrations in MUC5AC or MUC5B in response to SARS-CoV-2 infection are likely due to inflammation, though the responsible mechanisms have yet to be determined. Thus, we also provide a proposed model highlighting mechanisms that can contribute to acute and sustained mucus abnormalities in SARS-CoV-2, with an emphasis on inflammatory cells and mediators, including mast cells and histamine. Last, we bring to light the challenges of studying abnormal mucus production in SARS-CoV-2 infections and discuss the strengths and limitations of model systems commonly used to study COVID-19. The evidence to date suggests that ferrets, nonhuman primates, and cats may have advantages over other models to investigate mucus in COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.